Author: Kathryn Tucker
-
Ninth Circuit ducks merits in nation’s first legal challenge to allow access to psilocybin in end-of-life care under “Right-To-Try” laws
Bipartisan Congressional support for allowing terminal patients to seek relief from anxiety and depression in alignment with ongoing international research on the effectiveness of psilocybin in mental health care Statement The Ninth Circuit’s opinion today, January 31, 2022, finding that the agency action in this matter was not final – “the DEA’s response letter was…
-
Court Hears Argument in Landmark Case Seeking to Open Access to Psilocybin Therapy
THE NATION’S FIRST LEGAL CHALLENGE TO ALLOW PSILOCYBIN THERAPY IN END-OF-LIFE CARE UNDER “RIGHT-TO-TRY” LAW HEARD BY THE NINTH CIRCUIT COURT OF APPEALS: Cancer patients seek relief from anxiety and depression in alignment with ongoing research on the effectiveness of psilocybin in mental health care. Time: 1 p.m. PST, Thursday, September 2nd, 2021 Pasadena Virtual…
-
Amici Curiae Supporting Case Seeking to Compel DEA to Allow Access to Psilocybin Therapy for Seriously Ill Patients
A Seattle palliative care physician, co-director of an integrative oncology clinic, and a number of his patients with advanced cancer have sued the Drug Enforcement Administration (DEA) in a case seeking to compel the DEA to allow access to psilocybin therapy for patients with serious illness under state and federal Right to Try (RTT) laws.…
-
Opening Access to Psilocybin Therapy for Seriously Ill Patients: The Petitioners’ Opening Brief in AIMS et al. v DEA
Emerge Law Group is proud to represent a Seattle palliative care physician and co-director of an integrative oncology clinic, and a number of his patients with advanced cancer in a case seeking to open access to psilocybin therapy for patients with serious illness under state and federal Right to Try laws. Well known patient rights…
-
Avenues to Access Psilocybin Therapy in Oregon, a New Palliative Care Tool for Patients Suffering Anxiety and Depression
Recent medical research is establishing the powerful therapeutic uses of psilocybin in the treatment of anxiety and depression suffered by patients with terminal illness, as well as other possible indications. Studies show that patients with advanced cancer suffering from treatment-resistant anxiety and/or depression experienced significant reductions in both anxiety and depression and improvements of mood…
-
Nation’s First Legal Challenge to Allow Psilocybin Therapy in End-of-Life Care Under “Right-To-Try ” Laws Moves Forward
On behalf of terminally ill patients suffering anxiety and depression, we announce an advocacy effort to open access to psilocybin for terminally ill patients under state and federal “Right to Try” (RTT) laws. Well known patient rights advocate Kathryn Tucker, when she was Co-Chair of the Psychedelic Practice Group of Emerge Law Group and currently…
-
Cooperative Federalism Returns with the Biden Administration: Implications for Cannabis as well as Psilocbyin
In November 2020, Oregon voters approved a first of its kind initiative to make psilocybin therapy legal under Oregon state law. The Oregon Psilocybin Services Act (PSA) is heavily regulatory, establishing a two year ‘development period’ for development of regulations by the Oregon Health Authority (OHA), advised by a Psilocybin Advisory Board to be established…
-
First of its Kind Advocacy Effort to Open Access to Psilocybin for Terminally Ill Patients
Kathryn Tucker, Special Counsel at Emerge Law Group and now Special Advocacy Advisor for the National Psychedelics Association represented her client, the Advanced Integrative Medical Science Institute (AIMS), a leading oncology clinic in Seattle, and its co-director Sunil K. Aggarwal, MD, PhD, a noted palliative care specialist, in AIMS’ novel effort to seek permission from…
